Volume 70, Number 19, May 6, 2008
About this course
- Released: 05/05/2008
- Expires: 05/06/2010
Learning Objectives:
Upon completion of the article by Simpson et al., the participant should be able to:
• Discuss the pharmacological mechanism underlying the efficacy of botulinum toxin
• List the current United States Food and Drug Administration indications for botulinum neurotoxin serotypes A and B
• Discuss the findings from this evidence-based review regarding the efficacy of botulinum toxin for the treatment of adult and childhood spasticity
Core Competencies:
The article by Simpson et al. covers the following core competencies:
• Medical Knowledge
• Systems-based Practice
Learning Objectives:
Upon completion of the article by Simpson et al., the participant should be able to:
• Discuss the findings from this evidence-based review of the efficacy of botulinum toxin for the treatment of movement disorders
• Discuss recommendations for future research into the efficacy of botulinum toxin for the treatment of movement disorders
Core Competencies:
The article by Simpson et al. covers the following core competencies:
• Medical Knowledge
• Systems-based Practice
Author Disclosures: Refer to Information and Author section available in the Tool Bar for each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
ACCREDITATION STATEMENT
The American Academy of Neurology designates that participants will receive 1.5 AMA PRA Category 1 CME credits if both CME courses for the issue are completed. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
PARTICIPANTS
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
CREDITS
The American Academy of Neurology designates that participants will receive 1.5 AMA PRA Category 1 CME credits if both CME courses for the issue are completed.
The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
DISCLOSURES
Steven Lewis, MD, has received personal compensation in an editorial capacity for the National Board of Medical Examiners and the American College of Physicians; Paul Schulz, MD, has received personal compensation for activities with Pfizer.
COMMERCIAL SUPPORT
This CME program receives no commercial support.
